Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
3 ASX Stocks Jump as Key Business Updates Emerge
Source: Kapitales Research
Highlights
Three ASX-listed companies recorded double-digit share price gains during the session.
Recent announcements covered FDA regulatory progress, employee equity issuance and FY26 financial performance.
Two companies are also set to join the S&P/ASX 300 Index from 21 September 2026.
ASX Shares in Focus
Several ASX-listed companies recorded significant gains, with Echo IQ Limited (ASX: EIQ), SKS Technologies Group Limited (ASX: SKS) and The Star Entertainment Group Limited (ASX: SGR) among the stocks in focus. Echo IQ shares last traded at AU$0.775, gaining AU$0.185, or 31.36%. SKS Technologies was trading at AU$9.190, up AU$1.199, or 15.02%, while The Star Entertainment Group rose AU$0.019, or 14.81%, to AU$0.155.
Echo IQ Advances FDA Clearance Process
In an announcement dated 17 September 2026, Echo IQ provided an update on its EchoSolv HF 510(k) application with the US Food and Drug Administration (FDA). The company said it had begun working with regulatory consultants and legal counsel to address matters raised in the FDA's Not Substantially Equivalent determination. Echo IQ’s review found that the matters raised concerned statistical analysis used to support clinical validation, rather than the company’s underlying technology or core functionality. The company is assessing several pathways, including an administrative appeal, an FDA Ombudsman review and a new 510(k) submission.
SKS Technologies Issues Employee Shares
SKS Technologies released an Appendix 2A on 16 September 2026, seeking quotation of 74,462 fully paid ordinary shares issued under its Employee Equity Incentive Scheme. The securities were issued in lieu of cash amounts relating to FY26 performance bonuses at AU$7.8215 per share, based on the five-day VWAP to 4 September 2026. A 24-month holding lock applies under the company's employee equity plan.
The Star Reports FY26 Results
The Star reported normalised FY26 revenue of AU$1.101 billion in its results released on 31 August 2026, while its normalised EBITDA loss narrowed to AU$16.1 million, compared with AU$76.2 million in FY25. Statutory NPAT was a loss of AU$307.3 million. The company ended FY26 with AU$267 million in cash and cash equivalents as of 30 June 2026.
Index Changes Add Another Focus
The S&P Dow Jones Indices announcement dated 4 September 2026 detailed the changes resulting from the September quarterly review of the S&P/ASX indices. Echo IQ Limited and SKS Technologies Group Limited were among the companies added to the S&P/ASX 300 Index, with the changes set to take effect before the market opens on 21 September 2026. The index inclusion comes as both companies experience notable market activity. Echo IQ shares have gained 31.36% to AU$0.775, while SKS Technologies shares have risen 15.02% to AU$9.190. The upcoming index changes will therefore form another development for investors tracking the companies and their market positioning. The quarterly rebalance also includes several other additions and removals across the S&P/ASX 300, reflecting changes arising from the September review. The updated index constituents are scheduled to become effective from the start of trading on 21 September 2026.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
Includes 7 days of our daily research report emails and access to the member area.
AI analysis, watchlists and model portfolios run on the free plan
(5 AI credits a month, 1 watchlist). The AI portfolio trial on our
plans page
is a separate offer.
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
3 ASX Stocks Jump as Key Business Updates Emerge
Highlights
ASX Shares in Focus
Several ASX-listed companies recorded significant gains, with Echo IQ Limited (ASX: EIQ), SKS Technologies Group Limited (ASX: SKS) and The Star Entertainment Group Limited (ASX: SGR) among the stocks in focus. Echo IQ shares last traded at AU$0.775, gaining AU$0.185, or 31.36%. SKS Technologies was trading at AU$9.190, up AU$1.199, or 15.02%, while The Star Entertainment Group rose AU$0.019, or 14.81%, to AU$0.155.
Echo IQ Advances FDA Clearance Process
In an announcement dated 17 September 2026, Echo IQ provided an update on its EchoSolv HF 510(k) application with the US Food and Drug Administration (FDA). The company said it had begun working with regulatory consultants and legal counsel to address matters raised in the FDA's Not Substantially Equivalent determination. Echo IQ’s review found that the matters raised concerned statistical analysis used to support clinical validation, rather than the company’s underlying technology or core functionality. The company is assessing several pathways, including an administrative appeal, an FDA Ombudsman review and a new 510(k) submission.
SKS Technologies Issues Employee Shares
SKS Technologies released an Appendix 2A on 16 September 2026, seeking quotation of 74,462 fully paid ordinary shares issued under its Employee Equity Incentive Scheme. The securities were issued in lieu of cash amounts relating to FY26 performance bonuses at AU$7.8215 per share, based on the five-day VWAP to 4 September 2026. A 24-month holding lock applies under the company's employee equity plan.
The Star Reports FY26 Results
The Star reported normalised FY26 revenue of AU$1.101 billion in its results released on 31 August 2026, while its normalised EBITDA loss narrowed to AU$16.1 million, compared with AU$76.2 million in FY25. Statutory NPAT was a loss of AU$307.3 million. The company ended FY26 with AU$267 million in cash and cash equivalents as of 30 June 2026.
Index Changes Add Another Focus
The S&P Dow Jones Indices announcement dated 4 September 2026 detailed the changes resulting from the September quarterly review of the S&P/ASX indices. Echo IQ Limited and SKS Technologies Group Limited were among the companies added to the S&P/ASX 300 Index, with the changes set to take effect before the market opens on 21 September 2026. The index inclusion comes as both companies experience notable market activity. Echo IQ shares have gained 31.36% to AU$0.775, while SKS Technologies shares have risen 15.02% to AU$9.190. The upcoming index changes will therefore form another development for investors tracking the companies and their market positioning. The quarterly rebalance also includes several other additions and removals across the S&P/ASX 300, reflecting changes arising from the September review. The updated index constituents are scheduled to become effective from the start of trading on 21 September 2026.
Note- All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au